

May 3, 2021

Representative Adam Kinzinger  
2245 Rayburn House Office Building  
Washington, D.C., 20515

Representative Kurt Schrader  
2431 Rayburn House Office Building  
Washington, D.C., 20515

Dear Representative Kinzinger and Representative Schrader,

On behalf of Vizient, Inc., I am pleased to offer our endorsement and support for H.R 2815, the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act. This bipartisan legislation would take important steps to increase the reimbursement for certain biosimilar drugs. Encouraging the usage of these biosimilars, which are safe, effective and generally less-costly alternatives to branded biologic medications, will result in significant patient savings across the health system.

Vizient, Inc. is the nation's largest health care performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation's acute care providers, which includes 95% of the nation's academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

Vizient and our member hospitals appreciate the commitment from Congress in identifying and advancing new approaches to encourage more competition among pharmaceuticals. That competition is essential in reducing health care costs for patients, providers and the health care system broadly. Your legislation would take an important step in bolstering competition by supporting the development and adoption of biosimilar medications. This legislation would provide a temporary reimbursement increase for hospitals and doctors that utilize biosimilar drugs from the average sales price (ASP) of the drug plus 6% to the ASP plus 8%. With the significantly higher cost of biologic medications, this temporary increase in reimbursement would help close the financial gap between biologics and biosimilars and incentivize more widespread adoption of these safe, cost-effective medications.

We are pleased to support this legislation and encourage its swift passage. Please do not hesitate to contact me at [shoshana.krilow@vizientinc.com](mailto:shoshana.krilow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow  
Senior Vice President, Public Policy & Government Relations